At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 9, 2022
Dr. Albala on financial implications of emergence of PSMA-PET imaging
Author(s)Urology Times staff
“What’s important is that we get these studies approved so that our patients aren’t suffering any further economic burdens by having this new type of imaging being put forward,” says David Albala, MD.
Advertisement
In this video, urologist David Albala, MD, explains financial issues related to the emergence of PSMA-PET imaging as a critical component of the prostate cancer management paradigm. Albala is discussing PSMA-PET imaging during the CME program at the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5